Market overview
The global ergothioneine (EGT) market is worth USD 110 mn in 2026 and is forecast to reach USD 575 mn by 2036, growing at a 18.0% CAGR. United States is the largest country market and Dietary supplements is the largest by application segment.
| Scope | Ergothioneine, a sulphur-containing antioxidant amino acid produced by fermentation, extraction or synthesis and sold to supplement, cosmetic and food makers. |
|---|---|
| Industry | Food and Beverage |
| Value 2025 | USD 90 mn |
| Value 2026 | USD 110 mn |
| Value 2036 | USD 575 mn |
| CAGR 2026-2036 | 18.0% |
| Volume 2026 | 56.6 tonnes |
| Volume 2036 | 402 tonnes |
| Average price 2026 | USD 1,940,000 per tonne |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Ergothioneine (EGT) market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 110 mn |
| 2027 | USD 130 mn |
| 2028 | USD 153 mn |
| 2029 | USD 180 mn |
| 2030 | USD 213 mn |
| 2031 | USD 251 mn |
| 2032 | USD 296 mn |
| 2033 | USD 350 mn |
| 2034 | USD 413 mn |
| 2035 | USD 487 mn |
| 2036 | USD 575 mn |
Ergothioneine (EGT) market segmentation
By application
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Dietary supplements | 46.0% | 44.6% | USD 51 mn | 17.6% |
| Cosmetics | 30.0% | 34.4% | USD 33 mn | 19.6% |
| Functional foods and beverages | 16.0% | 15.5% | USD 18 mn | 17.6% |
| Pharmaceutical and other | 8.0% | 5.5% | USD 8.8 mn | 13.7% |
By production route
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Fermentation | 62.0% | 74.5% | USD 68 mn | 20.2% |
| Mushroom extraction | 24.0% | 14.5% | USD 26 mn | 12.2% |
| Chemical synthesis | 14.0% | 11.0% | USD 15 mn | 15.2% |
By product form
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Pure powder and crystal | 54.0% | 50.0% | USD 59 mn | 17.1% |
| Capsules and softgels | 22.0% | 24.0% | USD 24 mn | 19.0% |
| Premixes and liquids | 24.0% | 26.0% | USD 26 mn | 18.9% |
By purity
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Above 98% | 46.0% | 48.0% | USD 51 mn | 18.5% |
| 90 to 98% | 30.0% | 30.0% | USD 33 mn | 18.0% |
| Below 90% | 24.0% | 22.0% | USD 26 mn | 17.0% |
By sales channel
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Business-to-business ingredient | 56.0% | 52.0% | USD 61 mn | 17.1% |
| Direct online | 24.0% | 28.0% | USD 26 mn | 19.8% |
| Pharmacy and retail | 20.0% | 20.0% | USD 22 mn | 18.0% |
Top 25 countries for ergothioneine (EGT) by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 89.0% of 2026 revenue and the 25 countries below together hold 96.6%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 31 mn | 28.0% | USD 161 mn | 18.0% |
| 2 | China | USD 18 mn | 16.0% | USD 118 mn | 21.0% |
| 3 | Japan | USD 15 mn | 14.0% | USD 62 mn | 15.0% |
| 4 | South Korea | USD 8.8 mn | 8.0% | USD 46 mn | 18.0% |
| 5 | Germany | USD 6.6 mn | 6.0% | USD 29 mn | 16.1% |
| 6 | France | USD 5.5 mn | 5.0% | USD 26 mn | 17.0% |
| 7 | United Kingdom | USD 4.4 mn | 4.0% | USD 21 mn | 17.1% |
| 8 | Australia | USD 3.3 mn | 3.0% | USD 17 mn | 18.0% |
| 9 | Canada | USD 3.3 mn | 3.0% | USD 17 mn | 18.0% |
| 10 | Singapore | USD 2.2 mn | 2.0% | USD 14 mn | 20.2% |
| 11 | Taiwan | USD 1.6 mn | 1.4% | USD 8.3 mn | 18.1% |
| 12 | Italy | USD 1.3 mn | 1.2% | USD 6.8 mn | 18.1% |
| 13 | Switzerland | USD 1.1 mn | 1.0% | USD 5.6 mn | 18.1% |
| 14 | Netherlands | USD 0.87 mn | 0.8% | USD 4.6 mn | 18.1% |
| 15 | Spain | USD 0.71 mn | 0.7% | USD 3.7 mn | 18.0% |
| 16 | Thailand | USD 0.58 mn | 0.5% | USD 3.0 mn | 18.0% |
| 17 | Hong Kong | USD 0.48 mn | 0.4% | USD 2.5 mn | 18.0% |
| 18 | Malaysia | USD 0.40 mn | 0.4% | USD 2.1 mn | 18.0% |
| 19 | Israel | USD 0.32 mn | 0.3% | USD 1.7 mn | 18.0% |
| 20 | United Arab Emirates | USD 0.26 mn | 0.2% | USD 1.4 mn | 18.0% |
| 21 | Brazil | USD 0.22 mn | 0.2% | USD 1.1 mn | 18.0% |
| 22 | India | USD 0.18 mn | 0.2% | USD 1.0 mn | 19.4% |
| 23 | Sweden | USD 0.14 mn | 0.1% | USD 0.75 mn | 18.0% |
| 24 | Denmark | USD 0.12 mn | 0.1% | USD 0.63 mn | 18.0% |
| 25 | Belgium | USD 99 thousand | 0.09% | USD 0.52 mn | 18.0% |
| Rest of world | USD 3.8 mn | 3.4% | USD 18 mn | 17.1% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Tetrahedron
- Blue California
- Merck KGaA
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the ergothioneine (EGT) market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 18.0% is calculated from the resulting values.
The market is divided by application, by production route, by product form, by purity, by sales channel. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the ergothioneine (EGT) market?
The global ergothioneine (EGT) market is estimated at USD 90 mn in 2025 and USD 110 mn in 2026.
How fast will the ergothioneine (EGT) market grow?
It is forecast to reach USD 575 mn by 2036, a compound annual growth rate of 18.0% from 2026, an increase of USD 465 mn.
Which country is the largest market for ergothioneine (EGT)?
United States is the largest market by revenue at USD 31 mn in 2026, 28.0% of the global total. The three largest countries together hold 58.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 21.0% a year from 2026 to 2036.
Which ergothioneine (EGT) segment is largest?
In the by application split, Dietary supplements is the largest segment with 46.0% of 2026 revenue.
Who are the leading ergothioneine (EGT) companies?
Global leaders include Tetrahedron, Blue California, Merck KGaA.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Food and Beverage
- Chickpea ProteinUSD 109 mn · 16.0% CAGR
- Precision Fermentation Dairy Protein IngredientsUSD 112 mn · 24.0% CAGR
- Cocoa-Free & Alternative ChocolateUSD 118 mn · 22.0% CAGR
- King CakesUSD 124 mn · 3.6% CAGR
- Vegan TunaUSD 124 mn · 12.0% CAGR
- Fava Bean ProteinUSD 95 mn · 11.5% CAGR
- Hydrolyzed Egg MembraneUSD 93 mn · 8.6% CAGR
- Pet Food PulverizerUSD 88 mn · 4.0% CAGR